Connect with us

Media OutReach

1 in 4 Malaysians at Risk: Alpro Pharmacy Leads National Movement to Reverse Prediabetes

Published

on

KUALA LUMPUR, MALAYSIA – Media OutReach Newswire – 21 May 2025 – With one in four Malaysian adults unknowingly living with prediabetes, the country is facing a silent but escalating health crisis. Research shows that one in ten individuals with prediabetes will develop type 2 diabetes within a year, and up to 70% will progress within a decade if no action is taken (Sources: National Health and Morbidity Survey 2019; International Diabetes Federation).

(From left: Dietitian Chua Kai Jia (Professional Care & Development Manager cum Dietitian, Alpro Pharmacy); Pharmacist Anson Tan (Category Manager, Alpro Pharmacy); Mr. Yan Xiangrong (Country Manager, Yuwell Malaysia); Mr. Nicholas Tham (Commercial Director, Ethos Healthcare); Professor Dr. Hasniza (Deputy Vice Chancellor (Academic & International), University of Malaya); Ms. Pixie Yee (Managing Director, Merck Malaysia & General Manager, Merck Healthcare Malaysia and Singapore); Ms. Elsie Low (General Manager, Powerlife Malaysia); Pharmacist Ng Yi Ling (Professional Care & Development Manager, Alpro Pharmacy))

In response to this urgent need, Alpro Pharmacy has launched the ASAP Programme (Alpro Stand Against Prediabetes) a nationwide health campaign that began in April 2025. This initiative is designed to raise early awareness, promote timely screening, and provide accessible, professional care to help Malaysians reverse prediabetes before it becomes a lifelong condition.

As part of this commitment, Alpro is offering 10,000 free HbA1c tests to high-risk individuals across more than 300 Alpro touchpoints nationwide, from April through June 2025.

With a focus on those with a family history of diabetes and those at higher risk due to age or weight, the ASAP Programme empowers individuals to take proactive steps towards better health. Through early detection and pharmacist-led counseling, nutrition guidance, and lifestyle modifications, participants can potentially reverse their condition.

Beyond individual action, the programme also reinforces the vital role that primary care providers—including community pharmacists, community nutritionists and dietitians, and general practitioners—play in delivering preventive healthcare directly to the public. By bringing early intervention into the heart of the community, the programme ensures that help is accessible, timely, and coordinated.

This national effort is made possible through a strong multidisciplinary collaboration between Alpro Pharmacy, Merck Sdn. Bhd., University of Malaya, Yuwell Malaysia, Ethos Healthcare, and Powerlife Malaysia. United by a shared vision for preventive healthcare, these partners bring together medical innovation, digital health tools, academic research, and nutritional science to combat one of Malaysia’s most pressing chronic health challenges. “Prediabetes is not a life sentence—it’s a second chance,” said Ph. Lim En Ni, Chief Pharmacist and Engagement Director of Alpro Pharmacy. “Through the ASAP Programme, we’re reaching people before diabetes does—offering them the tests, intervention, and ongoing support they need to make lasting changes. Our aim is to stop diabetes before it starts.”

For Merck Sdn. Bhd., the programme aligns with its commitment to early intervention in chronic disease.“The ASAP Programme puts prevention into action—on the ground, led by pharmacists,” said Ms. Pixie Yee, Managing Director of Merck Malaysia and General Manager of Merck Healthcare Malaysia and Singapore. “It’s meaningful because it reaches people before complications begin. As healthcare leaders, we must shift the focus from delayed treatment to early empowerment.”

A core component of the campaign is a research collaboration with the University of Malaya to evaluate the impact of pharmacist-led interventions in identifying and managing prediabetes. The study explores how HbA1c screening, paired with pharmacological and lifestyle guidance, can delay or even prevent the onset of type 2 diabetes. Findings are expected to help shape future national healthcare strategies and support the standardisation of pharmacy-based chronic disease prevention in Malaysia. “This campaign is more than awareness—it’s a chance to validate the impact of pharmacists in chronic disease prevention,” said Professor Dr. Hasniza, Deputy Vice Chancellor, University of Malaya.

The ASAP Programme aims to amplify a clear and urgent public health message: prediabetes is reversible, early action matters, and no one should wait for symptoms before seeking help. With professional support and free screening made easily available across the country, this campaign proves that diabetes can be stopped—before it starts.

Malaysians are encouraged to participate by visiting any Alpro Pharmacy outlet during the campaign period. For full campaign details, eligibility information, and outlet locations, please visit: https://bit.ly/AlproASAP

Let’s act ASAP — because the best way to fight diabetes is to stop it before it starts.
Hashtag: #alpro

The issuer is solely responsible for the content of this announcement.

Alpro Pharmacy

With a humble beginning starting with a single pharmacy outlet in the small town of Port Dickson in 2002, Alpro Pharmacy is now a diversified community chain pharmacy that provides comprehensive primary healthcare solutions via over 300 outlets including Alpro Pharmacy, Alpro Clinic, Alpro Physio and Alpro Baby, both online and offline, nationwide. It is supported by a team of more than 650 healthcare professionals, ranging from doctors, pharmacists, nutritionists, dietitians to physiotherapists and many other healthcare professionals.

Serving more than 3 million families in Malaysia, Alpro Pharmacy is the first and only community pharmacy in the country to provide RM1 million product liability insurance to safeguard the supply of genuine medications. With over 500,000 prescriptions filled per year, Alpro Pharmacy is also the largest prescription pharmacy chain in Malaysia.

For more information, please visit .

Advertisement

Media OutReach

St. George’s University Prepares Future South Korean Physicians for the Growing Global Cancer Care Challenge

Published

on

SEOUL, SOUTH KOREA – Media OutReach Newswire – 4 February 2026 – Rising global cancer incidence is straining healthcare systems, which already face workforce shortages. In East Asia, the number of trained physicians in cancer care, spanning diagnosis, treatment coordination, and long-term management—has not met the increasing demand. According to the Global Cancer Observatory, South Korea reported over 230,000 new cancer cases and more than 97,000 fatalities in 2022. A recent original academic research by Myongji College and The Catholic University of Korea warned that simply increasing medical school enrollments alone does not fix shortages in key specialties and underserved regions where medical demand is rising fastest.

Source: St. George’s University

Recognizing the importance of addressing workforce shortage in South Korea, St. George’s University (SGU) School of Medicine in Grenada, West Indies, highlights how its medical education approach supports the development of clinical competencies relevant to cancer care across healthcare settings.

These challenges reflect broader global trends, where cancer care increasingly depends on multidisciplinary teams rather than specialty expansion alone. SGU’s curriculum is designed to build a strong foundation in clinical diagnosis, patient communication and multidisciplinary care, which are essential skills for effective oncology and cancer-related care. Through anatomy labs, simulation-based learning, and integrated digital tools, students develop foundational clinical skills in structured, supervised environments designed to reflect real-world medical practice.

The curriculum also integrates traditional cadaveric dissection with modern 3D anatomical modeling. This blend helps students visualize the human body in a holistic way while reinforcing knowledge through their hands-on interaction. SGU’s simulation lab also enables medical students to have their first direct interaction with ill patients in a safe, simulated learning environment.

On top of core medical training, SGU offers early exposure to prevention, diagnosis and patient-centered care to prepare graduates to tackle complex health issues. SGU has developed long-standing relationships with more than 75 established hospitals and clinical centers in the US and UK. These clinical placements provide exposure to diverse patient populations and care environments, including settings where cancer diagnosis and management are part of routine clinical practice.

South Korean SGU alumni are contributing to healthcare systems through roles that intersect with cancer diagnosis, treatment coordination, and long-term patient care. For example, Dr. Julia Hweyryoung Cho, MD 2022 is practicing internal medicine, which plays a crucial role in cancer care. Internal medicine physicians are often involved in the initial diagnosis of cancer, managing complex medical conditions that may arise during treatment and providing long-term comprehensive care and survivorship planning for patients with a history of cancer.

In observance of World Cancer Day 2026, SGU encourages all medical professionals and organizations to collaboratively address global cancer care challenges. This includes recognizing and meeting the cancer healthcare needs of individuals and communities in South Korea.

For more information on the programs and tracks available through SGU School of Medicine, visit SGU’s website.Hashtag: #St.George’sUniversity

The issuer is solely responsible for the content of this announcement.

Continue Reading

Media OutReach

Finalists and Semifinalists for $1 Million Seeding The Future Global Food System Challenge Announced

Published

on

BONN, GERMANY – Newsaktuell – 3 February 2026 – The Seed Grant Finalists and Growth Grant and Seeding the Future Grand Prize Semifinalists of the 5th annual Seeding The Future Global Food System Challenge (GFSC) have been announced, marking a key milestone in the USD 1 million global Challenge supporting impactful and innovative solutions to transform food systems.

Created and funded by Seeding The Future Foundation and, for the first time, hosted by Welthungerhilfe (WHH), the Challenge attracted a record 1,600+ applications from innovator teams in 112 countries, underscoring growing global momentum for food systems transformation.

Following a multi-stage, rigorous international review process, 36 teams have advanced across three award levels. These include 16 Seed Grant Finalists (competing for 8 awards of USD 25,000), 12 Growth Grant Semifinalists (competing for 3 awards of USD 100,000), and 8 Seeding The Future Grand Prize Semifinalists (competing for 2 awards of USD 250,000).

“Hosting the GFSC reflects Welthungerhilfe’s commitment to accelerating bold, scalable innovations where they are needed most. This year’s diversity of solutions underscores the complexity of food system challenges and the creativity of innovators worldwide.” said Jan Kever, Head of Innovation at Welthungerhilfe

The submitted innovations span diverse themes and approaches, including climate-smart production, nutrient-dense foods, food loss reduction, and inclusive market models, reflecting the complexity and interconnected nature of today’s food systems challenges.

“The Seeding The Future Global Food System Challenge exists to catalyze impactful, bold, and scalable innovations that advance food systems transformation. We are excited to work alongside Welthungerhilfe as a trusted partner and host of the Challenge and are encouraged by the quality and diversity of innovations emerging from this first year of collaboration.” said Bernhard van Lengerich, Founder and CEO of Seeding The Future Foundation

While the number of awards is limited, all semifinalists and finalist applicants plus all applicants with any prior recognition of other innovation competitions can join the STF Global Food System Innovation Database and Network—currently in beta testing with the Food and Agriculture Organization of the United Nations—vastly expanding their visibility and reach across a global audience.

List of 2025 GFSC Seed Grant Finalists, Growth Grant and Seeding The Future Grand Prize Semifinalists

Find details here: welthungerhilfe.org/gfsc-finalists

Seeding The Future Grand Prize Semi-Finalists

Growth Grant Semi-Finalists

Seed Grant Finalists

Hashtag: #TheFutureGlobalFoodSystemChallenge

The issuer is solely responsible for the content of this announcement.

About Seeding The Future Foundation

STF is a private nonprofit dedicated to ensuring equitable access to safe, nutritious, affordable, and trusted food. It supports innovations that transform food systems and benefit both people and planet. More at .

About Welthungerhilfe
WHH is one of Germany’s largest private aid organizations, striving for a world without hunger since 1962. More at:

Continue Reading

Media OutReach

PolyU develops novel antibody targeting fat cell protein, offering new approach to treating metabolism-related liver cancer

Published

on

HONG KONG SAR – Media OutReach Newswire – 3 February 2026 – Liver cancer is one of the three deadliest cancers worldwide, and metabolic dysfunction-related cases have become increasingly common in recent years. A research team from The Hong Kong Polytechnic University (PolyU) has identified a protein secreted by fat cells that promotes cancer growth and has successfully developed a novel antibody that neutralises this protein, marking a significant breakthrough in impeding the progression of liver cancer. The research findings have been published in the Journal of Clinical Investigation.

Prof. Terence Lee, Associate Head and Professor of the PolyU Department of Applied Biology and Chemical Technology, and his research team have developed a novel antibody targeting the adipocyte-derived protein FABP4, offering a new approach to treating metabolism-related liver cancer.

Metabolic dysfunction-associated steatotic liver disease (MASLD), commonly known as fatty liver disease, currently affects around a quarter of the global population and is an important risk factor for liver cancer. In affected individuals, fat cells induce insulin resistance and chronic inflammation, leading to excessive fat accumulation in the liver. This ultimately impairs liver function and may progress to liver cancer. Treatment options for MASLD-induced liver cancer remain limited and the effectiveness of current immunotherapies is suboptimal.

A breakthrough study led by Prof. Terence LEE, Associate Head and Professor of the PolyU Department of Applied Biology and Chemical Technology, and his research team has revealed that an adipocyte-derived protein, known as fatty acid-binding protein 4 (FABP4) is a key driver that accelerates tumour growth. Through mass spectrometry, the team confirmed that patients with MASLD-induced liver cancer had markedly elevated FABP4 levels in their serum. Further investigations showed that FABP4 activates a series of pro-proliferative signalling pathways within cells, causing cancer cells to multiply and grow more rapidly.

Prof. Lee’s team has successfully developed a monoclonal antibody that neutralises FABP4. This antibody not only inhibits the growth and proliferation of FABP4-driven cancer stem cells, but also enhances the ability of immune cells to combat cancer.

Prof. Lee said, “This neutralising antibody against FABP4 demonstrates significant potential in inhibiting tumour growth and activating immune cells, providing a complementary approach to current immunotherapy strategies. Our findings highlight that targeting adipocyte-derived FABP4 holds promise for treating MASLD-induced liver cancer.”

Prof. Lee added that gaining deeper insights into how adipocyte-derived FABP4 affects liver cancer cells helps to explicate the disease mechanisms of liver cancer, particularly in obese individuals. Intervening in the relevant signalling pathways could provide effective methods to combat this aggressive malignancy.

Prof. Lee believes that, as this adipocyte-targeted immunotherapy continues to mature, it will bring more treatment options to MASLD patients. He remarked, “If its efficacy can be proven in clinical trials, it could offer new hope to many affected individuals.”

The research is supported by the Innovation and Technology Fund of the Innovation and Technology Commission of the Government of the Hong Kong Special Administrative Region of the People’s Republic of China. PolyU has filed a non-provisional patent for the developed antibody and is continuing to optimise its binding affinity to facilitate future clinical applications.
Hashtag: #PolyU #FattyLiver #Cancer #LiverCancer #理大 #香港理工大学 #肝癌 #癌症 #脂肪肝

The issuer is solely responsible for the content of this announcement.

Continue Reading

Trending